Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Francesco Casulli"'
Autor:
Renato Fanin, Rita Rizzi, Michele Baccarani, Patrizio Mazza, Emanuele Angelucci, Selenia Campagna, Silvia Cantoni, Enrica Gamba, Valerio De Stefano, Felicetto Ferrara, Giuseppe Visani, Marzia Defina, Franca Soldano, Sergio Amadori, Emilio Usala, Alfonso Zaccaria, Francesco Casulli, Alessia Tieghi, Antonella Fornaro, Miriam Isola, Luigi Gugliotta, Monica Bocchia, Marta Lisa Battista, Francesco Zaja, Nicola Vianelli
Previous observational studies suggest that rituximab may be useful in the treatment of primary immune thrombocytopenia (ITP). This randomized trial investigated rituximab efficacy in previously untreated adult ITP patients with a platelet count of 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::075770f87340e838aa95173f0f9da42d
http://hdl.handle.net/11365/10970
http://hdl.handle.net/11365/10970
Autor:
Fortunato Morabito, Lucio Catalano, Eugenio Piro, Sara Galimberti, Donato Mannina, Antonio Francesco Casulli, Sara Bringhen, Luca Baldini, Michele Cavo, Mario Boccadoro, Massimo Offidani, Patrizia Tosi, Salvatore Palmieri, Vincenzo Callea, Giuseppe Mele, Graziella Pinotti, Francesco Di Raimondo, Massimo Gentile, Antonio Palumbo, Pellegrino Musto, Maria Teresa Petrucci, Stefania Ciolli
Renal impairment (RI) is a severe complication throughout the course of multiple myeloma (MM). Bortezomib has been shown to be highly active in MM patients with RI. We designed this retrospective analysis to investigate the safety and efficacy of bor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b62de420fec1c6a457967a403b6e64fa
http://hdl.handle.net/2318/83393
http://hdl.handle.net/2318/83393
Autor:
Paola Tacchetti, Patrizia Tosi, Michele Cavo, Annamaria Brioli, Delia Cangini, Giuliana Leopardi, Elena Zamagni, Alessandro Gozzetti, Antonio Ledda, Francesco Casulli, Nicoletta Testoni, Massimo Offidani, Carolina Terragna, Affra Carubelli, Alessandro Petrucci, Lucia Pantani, Claudia Cellini, Michele Baccarani, Silvestro Volpe, Giulia Perrone, Chiara Nicci, Luciano Masini, Francesco Di Raimondo, Michela Ceccolini, Catello Califano, Francesca Patriarca, Lucio Catalano, Mauro Fiacchini
Publikováno v:
ResearcherID
Abstract 349 We report here on the final analysis of the multicenter phase II “Bologna 2002” study which incorporated thal-dex into double ASCT with high-dose melphalan (200 mg/m2) as front-line therapy for younger patients with symptomatic multi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fa59c7796c3e930643ae76ba1f60e3d
http://hdl.handle.net/20.500.11769/75921
http://hdl.handle.net/20.500.11769/75921
Autor:
Massimo Offidani, Mauro Fiacchini, Patrizia Tosi, Catia Bigazzi, Piero Maria Stefani, Paola Tacchetti, Elena Zamagni, Antonio De Vivo, Silvestro Volpe, Antonio Ledda, Francesca Patriarca, Giulia Perrone, Francesco Di Raimondo, Antonio Francesco Casulli, Michele Baccarani, Catello Califano, Michela Ceccolini, Filippo Ballerini, Michele Cavo, Annamaria Brioli
Purpose To assess potential benefits with thalidomide incorporated into double autologous stem-cell transplantation (ASCT) for younger patients with newly diagnosed multiple myeloma (MM). Patients and Methods One hundred thirty-five patients who rece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db58bdd5250c690a73d0d7900826d4a5
http://hdl.handle.net/20.500.11769/55503
http://hdl.handle.net/20.500.11769/55503
Autor:
Luca Baldini, Vincenzo Callea, Fortunato Morabito, Salvatore Palmieri, Graziella Pinotti, Maria Teresa Petrucci, Sara Galimberti, Pellegrino Musto, Massimo Gentile, Stefania Ciolli, Francesco Di Raimondo, Eugenio Piro, Sara Bringhen, Giuseppe Mele, Patrizia Tosi, Donato Mannina, Lucio Catalano, Massimo Offidani, Antonio Palumbo, Michele Cavo, Mario Boccadoro, Antonio Francesco Casulli
RI is a common and severe complication throughout the course of MM. Vel, either as single agent or combined with other drugs, has been shown to be highly active in MM pts with varying degrees of RI. We retrospectively analyzed the outcome of 105 pts
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a865446e98573b38e99cbe49feb31b98
http://hdl.handle.net/2318/118806
http://hdl.handle.net/2318/118806
Autor:
Mariacarla De Simone, Emanuele Angelucci, Alfonso Zaccaria, Silvia Cantoni, Miriam Isola, Luigi Gugliotta, Marta Lisa Battista, Anna Lia Molinari, Giuseppe Visani, Monica Bocchia, Felicetto Ferrara, Marzia Defina, Francesco Casulli, Franca Soldano, Selenia Campagna, Rita Rizzi, Michele Baccarani, Antonella Fornaro, Emilio Usala, Francesco Zaja, Patrizio Mazza, Valerio De Stefano, Nicola Vianelli, Alessia Tienghi, Sergio Amadori, Renato Fanin
Publikováno v:
Blood. 114:2415-2415
Abstract 2415 Poster Board II-392 We previously reported that in adults with primary immune thrombocytopenia (ITP) the addition of four weekly administrations of rituximab 375 mg/m2 to a single course of dexamethasone (40 mg daily for four days) impr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20df7d77b2ec5bdb87ce66147fa75895
https://doi.org/10.1182/blood.v114.22.2415.2415
https://doi.org/10.1182/blood.v114.22.2415.2415
Autor:
Rita Rizzi, Silvia Cantoni, Enrica Gamba, Renato Fanin, Sergio Amadori, Giuseppe Visani, Patrizio Mazza, Marta Lisa Battista, Valerio De Stefano, Francesco Casulli, Miriam Isola, Luigi Gugliotta, Monica Bocchia, Emanuele Angelucci, Michele Baccarani, Alfonso Zaccaria, Anna Lia Molinari, Antonella Fornaro, Selenia Campagna, Francesco Zaja, Felicetto Ferrara, Marzia Defina, Franca Soldano, Maria Carla De Simone, Emilio Usala, Alessia Tieghi, Nicola Vianelli, Mario Regazzi
Publikováno v:
Blood. 112:1-1
Introduction. Previous uncontrolled studies have highlighted the activity of rituximab in patients with idiopathic thrombocytopenic purpura (ITP) relapsed or refractory to standard treatments. To better address this effect, a prospective randomized (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7cacd09bb4d0fabb6ea111be29174dc4
https://doi.org/10.1182/blood.v112.11.1.1
https://doi.org/10.1182/blood.v112.11.1.1
Autor:
Piero Maria Stefani, Affra Carubelli, Michela Ceccolini, Sadia Falcioni, Claudia Cellini, Alessandro Gozzetti, Lucio Catalano, Patrizia Tosi, Francesca Patriarca, MC Pallotti, Matteo Renzulli, Michele Baccarani, Nicoletta Testoni, Giulia Perrone, Francesco Casulli, Carolina Terragna, Antonio Ledda, Francesco Di Raimondo, Lucia Pantani, Luciano Masini, Paola Tacchetti, Elena Zamagni, Mauro Fiacchini, Silvestro Volpe, Catello Califano, Chiara Nicci, Michele Cavo, Annamaria Brioli
Publikováno v:
ResearcherID
The phase II “Bologna 2002” clinical study incorporated thalidomide-dexamethasone (thal-dex) into double ASCT with melphalan (200 mg/m2) as frontline therapy for patients with symptomatic multiple myeloma (MM) and less than 65 years of age. By st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2d67ce81b8a681800848dc2680f56dd
https://doi.org/10.1182/blood.v110.11.447.447
https://doi.org/10.1182/blood.v110.11.447.447
Autor:
Vincenzo Mettivier, Antonella Prudenzano, Patrizio Mazza, Francesco Casulli, Giancarla Pricolo, Olimpia Finizio, Stefano Rocco, Carlo De Rosa, Lucia Bene, L Pezzullo
Publikováno v:
Blood. 106:4637-4637
Association between fludarabine (Fluda) and cytosine arabinoside (ARA-C) have shown in a variety of single arm studies an effective antileukemic effect with acceptable toxicity in high risk myelodisplasias and acute myeloid leukemias in elderly patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51910ab57989599136d2ea1fc37a3466
https://doi.org/10.1182/blood.v106.11.4637.4637
https://doi.org/10.1182/blood.v106.11.4637.4637
Autor:
Lelia Valdrè, Michela Ceccolini, Antonio Ledda, Affra Carubelli, Claudia Cellini, Michele Cavo, Annamaria Brioli, MC Pallotti, Giulia Perrone, Cristina Legnani, Lucio Catalano, Elisa Favaretto, Paola Tacchetti, Sadia Falcioni, Francesco Casulli, Alessandro Gozzetti, Francesca Patriarca, Michele Baccarani, Elena Zamagni, Luciano Masini, Catello Califano, Patrizia Tosi, Lucia Pantani, Gualtiero Palareti, Michela Cini, Silvestro Volpe
Publikováno v:
ResearcherID
Venous thromboembolism (VTE) has emerged as a major adverse event of primary induction therapy with thalidomide (thal) and dexamethasone (dex) for newly diagnosed multiple myeloma (MM). Aim of the present study was to investigate the relationship bet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0f48eb698cae8ebc697c0b84eaf9256
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000251101100253&KeyUID=WOS:000251101100253
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000251101100253&KeyUID=WOS:000251101100253